Funding Round

Synchron raises $75M Series C ahead of FDA pivotal trial filing

Bloomberg4/12/2026·04/12/26🌐 USA

Summary

Synchron closed a $75M Series C from ARCH Venture Partners, DFJ Growth, Tiger Global, and Khosla Ventures. The company also announced participation from Gates Frontier and Bezos Expeditions in bridge financing. Total funding now exceeds $145M. Round supports the planned COMMAND pivotal trial for FDA De Novo clearance.

Why it matters

The tech billionaire investor group — Gates, Bezos — alongside traditional life science VCs creates a unique coalition backing Synchron's endovascular approach. The COMMAND pivotal trial design will be the definitive test of whether lower surgical risk can compensate for potentially lower signal quality versus cortical implants.

#ALS#BCI#FDA#Industry#Neural Interfaces#Pivotal Trial#USA#Venture Capital

Want the full NeurotechMag Pro intelligence database?

Access 800+ papers, trials, patents, funding rounds and news items — updated daily.

Start free trial

Already a member? Sign in